A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 mg QD) and Placebo
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Dexlansoprazole (Primary) ; Lansoprazole
- Indications Erosive oesophagitis
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 14 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 28 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Jan 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Jun 2018.